Bellerophon Therapeutics (NASDAQ:BLPH) Research Coverage Started at StockNews.com

StockNews.com started coverage on shares of Bellerophon Therapeutics (NASDAQ:BLPH) in a research note published on Sunday. The brokerage issued a hold rating on the biotechnology company’s stock.

Bellerophon Therapeutics Price Performance

Bellerophon Therapeutics stock opened at $0.06 on Friday. The firm has a market cap of $672,650.00, a P/E ratio of -0.07 and a beta of 0.71. The business has a fifty day moving average of $0.04 and a two-hundred day moving average of $0.05. Bellerophon Therapeutics has a twelve month low of $0.03 and a twelve month high of $0.10.

Bellerophon Therapeutics Company Profile

Bellerophon Therapeutics, Inc, a clinical-stage therapeutics company, focuses on the development of products for the treatment of cardiopulmonary diseases in the United States. Its primary product is INOpulse, a proprietary pulsatile nitric oxide delivery platform for the treatment of pulmonary hypertension.